Black Rock Inc. Longboard Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,866,290 shares of LBPH stock, worth $35.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,866,290

Previous 869,879 114.55%

Holding current value

$35.2 Million

Previous $5.25 Million 668.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$18.89 - $26.06 $18.8 Million - $26 Million	996,411 Added 114.55%	1,866,290 $40.3 Million
Q4 2023 Feb 13, 2024	BUY	$3.68 - $6.5 $309,278 - $546,279	84,043 Added 10.69%	869,879 $5.25 Million
Q3 2023 Nov 13, 2023	BUY	$5.49 - $7.49 $248,329 - $338,795	45,233 Added 6.11%	785,836 $4.37 Million
Q2 2023 Aug 11, 2023	BUY	$4.19 - $10.05 $2.98 Million - $7.15 Million	711,581 Added 2451.87%	740,603 $5.44 Million
Q1 2023 May 12, 2023	BUY	$3.84 - $5.96 $36,487 - $56,631	9,502 Added 48.68%	29,022 $116,000

Q4 2022 Feb 13, 2023	BUY	$3.21 - $5.5 $1,999 - $3,426	623 Added 3.3%	19,520 $63,000
Q3 2022 Nov 14, 2022	SELL	$2.95 - $4.7 $8,360 - $13,319	-2,834 Reduced 13.04%	18,897 $70,000
Q2 2022 Aug 12, 2022	SELL	$2.96 - $5.38 $26,456 - $48,086	-8,938 Reduced 29.14%	21,731 $67,000
Q1 2022 May 12, 2022	BUY	$4.0 - $6.0 $50,304 - $75,456	12,576 Added 69.51%	30,669 $164,000
Q4 2021 Feb 10, 2022	BUY	$4.75 - $9.45 $2,232 - $4,441	470 Added 2.67%	18,093 $89,000
Q3 2021 Nov 09, 2021	SELL	$8.65 - $11.36 $3,252 - $4,271	-376 Reduced 2.09%	17,623 $156,000
Q2 2021 Aug 11, 2021	BUY	$7.95 - $17.3 $143,092 - $311,382	17,999 New	17,999 $164,000

Others Institutions Holding LBPH

# of Institutions

106

Shares Held

30M

Call Options Held

16.3K

Put Options Held

56.5K

View Full List

About Longboard Pharmaceuticals, Inc.

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $256M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

More about LBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account